DEAD/H-box helicase 11 like 8 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored DDX11L8 profile across patient tissues and cancer cell-line models. DDX11L8 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, DDX11L8 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, DDX11L8 RNA expression shows 8,751 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, BRCA, and TGCT as cancer lineages where DDX11L8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX11L8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX11L8 survival associations across molecular data types. DDX11L8 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX11L8 RNA expression–survival associations across cancer types. High DDX11L8 expression shows unfavorable associations in LIHC, ACC, KIRC, UCEC, LUSC and THCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for DDX11L8 RNA expression.
This table summarizes DDX11L8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for DDX11L8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX11L8 shows lower tumor expression in HNSC and KIRC and higher tumor expression in BRCA, BLCA, CHOL and COAD. The BRCA box plot shows higher DDX11L8 RNA expression in tumor versus normal tissue (log2 FC = +0.152, t-test p = .010).
This table shows molecular features associated with DDX11L8 in patient tissues and cancer cell lines. In patient samples, DDX11L8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
